Veracyte Reports Strong Q2 2025 Revenue Growth

Veracyte Inc ( (VCYT) ) has released its Q2 earnings. Here is a breakdown of the information Veracyte Inc presented to its investors.

Veracyte, Inc., a prominent player in the cancer diagnostics sector, is dedicated to enhancing cancer care through its innovative genomic tests and bioinformatic capabilities. In its latest earnings report for the second quarter of 2025, Veracyte reported a 14% increase in total revenue, reaching $130.2 million, driven by strong performance in its Decipher and Afirma tests. The company also recorded a significant increase in testing volume, with Decipher achieving a 28% growth. Despite a GAAP net loss of $1.0 million due to a $20.5 million impairment charge, Veracyte’s adjusted EBITDA improved by 49% year-over-year to $35.8 million. The company’s strategic focus on expanding its Decipher test for metastatic cancer patients and the successful restructuring of its French subsidiary are key highlights. Looking ahead, Veracyte has raised its full-year revenue guidance, reflecting confidence in sustained growth, supported by its robust platform and expanding clinical evidence base.